Molecular Markers Linked to Tamoxifen Failure in Breast Cancer
Author Information
Author(s): Julie A Vendrell, Katherine E Robertson, Patrice Ravel, Susan E Bray, Agathe Bajard, Colin A Purdie, Catherine Nguyen, Sirwan M Hadad, Ivan Bieche, Sylvie Chabaud, Thomas Bachelot, Alastair M Thompson, Pascale A Cohen
Primary Institution: Université de Lyon
Hypothesis
Can we identify molecular markers associated with tamoxifen failure in breast cancer?
Conclusion
A gene expression signature associated with tamoxifen failure was identified, which may help in managing ER-positive breast cancer.
Supporting Evidence
- A 47-gene signature was identified that discriminates between tamoxifen failure and control samples.
- Low expression of ESR1/ERα, IGFBP4, SNCG, BCL2, and FOS was associated with shorter overall survival.
- BCL2 and FOS were identified as independent prognostic markers associated with relapse-free survival.
Takeaway
This study found specific genes that can help doctors understand why some breast cancer patients don't respond to tamoxifen treatment.
Methodology
The study compared gene expression in tumor samples from patients who failed tamoxifen treatment with those who did not, using cDNA microarrays and RTQ-PCR.
Potential Biases
Potential biases may arise from the selection of patient cohorts and the retrospective nature of the study.
Limitations
The study is exploratory and the sample size is relatively small.
Participant Demographics
The study included 35 postmenopausal Caucasian women aged 41 to 92 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website